<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="307991">
  <stage>Registered</stage>
  <submitdate>30/05/2009</submitdate>
  <approvaldate>18/06/2009</approvaldate>
  <actrnumber>ACTRN12609000487213</actrnumber>
  <trial_identification>
    <studytitle>Antares Coronary Stent System to Facilitate Side Branch Interventions</studytitle>
    <scientifictitle>Treatment sucess with the Antares Stent System for Coronary Artery Stenting at or near a Major Sidebranch</scientifictitle>
    <utrn />
    <trialacronym>TOP II</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Coronary Stenting involves placing a metal mesh in a blood vessel in the heart to open a blockage.  The stent is inserted through a blood vessel in the arm or leg and is put in place by inflating a balloon inside the stent.  The stent cannot be removed from the blood vessel once it is in place.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bifurcation Treatment Success- assessed by a visual assessment blood flow and stenosis in both the main vessel and side branch.</outcome>
      <timepoint>Measured at the conclusion of the bifurcation procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major cardiac adverse events including cardiac death, myocardial infarction and Target Lesion Revascularization as determined by clinician observation.</outcome>
      <timepoint>Measured at 1 month, 6 months, and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sidebranch Access Success - an evaluation of the ability to access the sidebranch with wire, balloon, and/or stent, to perform sidebranch interventions following Antares stent placement in the main vessel</outcome>
      <timepoint>Determined at the conclusion of the bifurcation procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>symptomatic or documented myocardial ischemia, 
study lesion is a single bifurcation lesion that has not been previously treated, 
By angiograpic review the study lesion has a diameter and length appropriate for Antares Stent,</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute myocardial infarction, Shock, Stroke, Coagulopathy, Left  main coronary lesion, Total occlusion, Diffuse disease, thrombus or severe calcification, Previous Coronary Artery Bypass Graft (CABG) surgery,</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>16/06/2009</anticipatedstartdate>
    <actualstartdate>15/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>17/07/2009</actualenddate>
    <samplesize>300</samplesize>
    <actualsamplesize>1</actualsamplesize>
    <recruitmentstatus>Stopped early</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/08/2009</actuallastvisitdate>
    <dataanalysis>No data analysis planned</dataanalysis>
    <withdrawnreason>Other reasons/comments</withdrawnreason>
    <withdrawnreasonother>Company decided to re-design device with a drug-coating</withdrawnreasonother>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3168</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>TriReme Medical, Inc.</primarysponsorname>
    <primarysponsoraddress>7060 Koll Center Parkway
Suite 300
Pleasanton, CA 94566</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>TriReme Medical, Inc.</fundingname>
      <fundingaddress>7060 Koll Center Parkway
Suite 300
Pleasanton, CA 94566</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Robust Industries Pty. Ltd</sponsorname>
      <sponsoraddress>95 Stevedore Street Williamstown, 
Victoria, 3016</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study to evalute the use of the Antares Stent System in patients with coronary disease at a location where two vessels are meeting.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Charite Universitsmedizin Berlin</ethicname>
      <ethicaddress>Schumannstr 20/21
10098 Berlin</ethicaddress>
      <ethicapprovaldate>14/05/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Erin Tims</name>
      <address>7060 Koll Center Parkway
Suite 300
Pleasanton, CA 94566</address>
      <phone>+1 925-931-1300 ext 212</phone>
      <fax>+1 925-931-1361</fax>
      <email>etims@trirememedical.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Erin Tims</name>
      <address>7060 Koll Center Parkway
Suite 300
Pleasanton, CA 94566</address>
      <phone>+1 925-931-1300 ext 212</phone>
      <fax>+1 925-931-1361</fax>
      <email>etims@trirememedical.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Erin Tims</name>
      <address>7060 Koll Center Parkway
Suite 300
Pleasanton, CA 94566</address>
      <phone>+1 925-931-1300 ext 212</phone>
      <fax>+1 925-931-1361</fax>
      <email>etims@trirememedical.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>